(OSUR) OraSure Technologies - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68554V1089

Stock: HIV Tests, Hepatitis Tests, COVID Tests, Collection Devices, Alcohol Tests

Total Rating 19

Risk 43

Buy Signal -0.52

Medical Instruments & Supplies » Health Care Supplies
Age: 39.2y

Market Cap: 204m
Avg Trading Vol: 1.29M USD

ATR: 4.94%
Peers RS (IBD): 40.00

EPS (Earnings per Share)

EPS CAGR: 125.21%
EPS Trend: -21.2%

Last SUE: 2.16
Qual. Beats: 1

Revenue

Rev. CAGR: -20.35%
Rev. Trend: -79.1%

Last SUE: -0.43
Qual. Beats: 0

Risk 5d forecast
Volatility	47.4%
Relative Tail Risk	-4.16%

Reward TTM
Sharpe Ratio	-0.44
Alpha	-49.69

Character TTM
Beta	1.170
Beta Downside	1.290

Drawdowns 3y
Max DD	74.73%
CAGR/Max DD	-0.25

Description: OSUR OraSure Technologies December 31, 2025

OraSure Technologies Inc. (NASDAQ: OSUR) designs, manufactures and markets a broad portfolio of rapid diagnostic and specimen-collection products-including OraQuick HIV and HCV self-tests, InteliSwab COVID-19 rapid tests, and a suite of saliva-based genomic and microbiome collection kits-serving clinical labs, hospitals, public-health agencies and direct-to-consumer markets across the U.S., Europe, Africa and other regions.

Key recent metrics show FY 2023 revenue of $311 million, up 7 % year-over-year, driven primarily by sustained demand for point-of-care COVID-19 and infectious-disease tests; operating margin improved to 12 % as the company leveraged higher-margin self-test sales. The rapid-diagnostics sector is benefiting from two macro trends: (1) a shift toward decentralized, at-home testing accelerated by pandemic-era consumer behavior, and (2) expanding reimbursement coverage for FDA-cleared rapid assays, which together underpin a projected CAGR of 9 % for the global point-of-care market through 2028.

For a deeper quantitative dive, see the ValueRay platform’s OSUR analysis.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income: -60.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.10 > 0.02 and ΔFCF/TA -24.11 > 1.0
NWC/Revenue: 193.1% < 20% (prev 143.7%; Δ 49.38% < -1%)
CFO/TA -0.09 > 3% & CFO -39.9m > Net Income -60.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 7.03 > 1.5 & < 3
Outstanding Shares: last quarter (73.0m) vs 12m ago -2.12% < -2%
Gross Margin: 40.41% > 18% (prev 0.45%; Δ 3996 % > 0.5%)
Asset Turnover: 28.34% > 50% (prev 48.32%; Δ -19.99% > 0%)
Interest Coverage Ratio: -16.43 > 6 (EBITDA TTM -51.5m / Interest Expense TTM -3.75m)

Altman Z'' -1.32

A: 0.57 (Total Current Assets 283.0m - Total Current Liabilities 40.2m) / Total Assets 423.1m
B: -0.36 (Retained Earnings -152.9m / Total Assets 423.1m)
C: -0.14 (EBIT TTM -61.6m / Avg Total Assets 443.6m)
D: -2.83 (Book Value of Equity -173.0m / Total Liabilities 61.1m)
Altman-Z'' Score: -1.32 = CCC

Beneish M -2.52

DSRI: 1.61 (Receivables 24.3m/27.0m, Revenue 125.7m/224.3m)
GMI: 1.11 (GM 40.41% / 45.01%)
AQI: 1.45 (AQ_t 0.21 / AQ_t-1 0.14)
SGI: 0.56 (Revenue 125.7m / 224.3m)
TATA: -0.05 (NI -60.2m - CFO -39.9m) / TA 423.1m)
Beneish M-Score: -2.52 (Cap -4..+1) = A

What is the price of OSUR shares?

As of February 07, 2026, the stock is trading at USD 2.71 with a total of 453,354 shares traded.
Over the past week, the price has changed by -2.87%, over one month by +9.27%, over three months by +12.92% and over the past year by -30.69%.

Is OSUR a buy, sell or hold?

OraSure Technologies has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold OSUR.

StrongBuy: 1
Buy: 0
Hold: 3
Sell: 0
StrongSell: 0

What are the forecasts/targets for the OSUR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	4.5	66.1%
Analysts Target Price	4.5	66.1%
ValueRay Target Price	2.5	-8.1%

OSUR Fundamental Data Overview February 03, 2026

P/S = 1.6233
P/B = 0.5539
P/EG = 2.3
Revenue TTM = 125.7m USD
EBIT TTM = -61.6m USD
EBITDA TTM = -51.5m USD
Long Term Debt = 13.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.11m USD (from shortTermDebt, last quarter)
Debt = 13.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -203.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.04m USD (204.1m + Debt 13.5m - CCE 216.5m)
Interest Coverage Ratio = -16.43 (Ebit TTM -61.6m / Interest Expense TTM -3.75m)
EV/FCF = -0.02x (Enterprise Value 1.04m / FCF TTM -43.6m)
FCF Yield = -4200 % (FCF TTM -43.6m / Enterprise Value 1.04m)
FCF Margin = -34.72% (FCF TTM -43.6m / Revenue TTM 125.7m)
Net Margin = -47.92% (Net Income TTM -60.2m / Revenue TTM 125.7m)
Gross Margin = 40.41% ((Revenue TTM 125.7m - Cost of Revenue TTM 74.9m) / Revenue TTM)
Gross Margin QoQ = 43.46% (prev 42.12%)
Tobins Q-Ratio = 0.00 (Enterprise Value 1.04m / Total Assets 423.1m)
Interest Expense / Debt = 19.85% (Interest Expense 2.67m / Debt 13.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -48.7m (EBIT -61.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.03 (Total Current Assets 283.0m / Total Current Liabilities 40.2m)
Debt / Equity = 0.04 (Debt 13.5m / totalStockholderEquity, last quarter 362.0m)
Debt / EBITDA = 3.94 (negative EBITDA) (Net Debt -203.0m / EBITDA -51.5m)
Debt / FCF = 4.65 (negative FCF - burning cash) (Net Debt -203.0m / FCF TTM -43.6m)
Total Stockholder Equity = 387.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.58% (Net Income -60.2m / Total Assets 423.1m)
RoE = -15.55% (Net Income TTM -60.2m / Total Stockholder Equity 387.3m)
RoCE = -15.38% (EBIT -61.6m / Capital Employed (Equity 387.3m + L.T.Debt 13.5m))
RoIC = -12.57% (negative operating profit) (NOPAT -48.7m / Invested Capital 387.3m)
WACC = 10.57% (E(204.1m)/V(217.5m) * Re(10.23%) + D(13.5m)/V(217.5m) * Rd(19.85%) * (1-Tc(0.21)))
Discount Rate = 10.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.35%
Fair Price DCF = unknown (Cash Flow -43.6m)
EPS Correlation: -21.18 | EPS CAGR: 125.2% | SUE: 2.16 | # QB: 1
Revenue Correlation: -79.10 | Revenue CAGR: -20.35% | SUE: -0.43 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.15 | Chg30d=+0.001 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.54 | Chg30d=-0.086 | Revisions Net=-1 | Growth EPS=+16.6% | Growth Revenue=+3.7%

Additional Sources for OSUR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle